Anti-murine Il1rl1 T-BsAbs ± IL-15 superagonist reduces leukemia blasts, LSCs and reverses tumor microenvironment-mediated immune tolerance to extend survival in immunocompetent models of AML. This evidence concerns the gene IL1RL1 and neoplasm.